stockrow
Friday 6 November 2026
Export OVID’s income statement to Excel — free account
Ovid Therapeutics
OVID Healthcare Biotechnology
Ovid Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $7.3 million, up 1,181.3% from fiscal 2024.
- Revenue
- +463.9%
- EPS
- −33.3%
- Free cash flow
- −268.5%
- Total debt
- −11.7%
Quarter to June 2026, against a year earlier
2.87
0.29
+11.24%
Follow OVID
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | 13 | 208 | 2 | 0 | 1 | 7 | 8 | (10.5%) | 1 | 0 | 11 | +13.8% | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | +100.0 pt | ||||||
| EBT | (22) | (65) | (52) | (60) | (81) | 124 | (54) | (52) | (26) | (17) | (34) | (2.8%) | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | (642.26) | 59.58 | (3,604.78) | (13,351.79) | (4,670.14) | (240.13) | (439.11) | (240.1) pt | ||||||
| Net income | (22) | (65) | (52) | (60) | (81) | 123 | (54) | (52) | (26) | (17) | (34) | (2.8%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 3.09 | 0.02 | 0.01 | 0.01 | 0.10 | 0.04 | n/m | |||||
| Earnings | (2.28) | (3.35) | (2.11) | (1.54) | (1.39) | 1.78 | (0.77) | (0.74) | (0.37) | (0.23) | (0.23) | (22.5%) | ||||||
| Cash flow | (1.81) | (1.63) | (1.85) | (1.30) | (0.88) | 1.76 | (0.78) | (0.65) | (0.79) | (0.52) | (0.28) | (12.9%) | ||||||
| Capex | (0.02) | 0.00 | (0.01) | (0.01) | (0.01) | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (1.83) | (1.63) | (1.86) | (1.31) | (0.89) | 1.75 | (0.80) | (0.65) | (0.79) | (0.52) | (0.28) | (13.0%) | ||||||
| Book value | 5.01 | 4.31 | 1.58 | 1.79 | 0.75 | 2.66 | 1.88 | 1.24 | 0.96 | 1.77 | 1.06 | (10.9%) | ||||||
| Shares, m | 10 | 19 | 25 | 39 | 58 | 67 | 70 | 71 | 71 | 74 | 120 | +25.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 1.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.3 | |||||
| P/S | — | — | — | — | 0.00 | 0.00 | 0.65 | 597.77 | 116.51 | 16.57 | 72.14 | 121.9 | ||||||
| P/B | — | — | — | — | 3.09 | 1.21 | 1.03 | 2.67 | 0.97 | 0.92 | 2.70 | 1.6 | ||||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 0.11 | 365.43 | 46.44 | 8.62 | 58.65 | 70.1 | ||||||
| EV/FCF | — | — | — | — | (1.21) | 0.24 | (0.42) | (3.12) | (0.47) | (1.63) | (8.39) | (1.1) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (18) | (31) | (46) | (51) | (52) | 119 | (55) | (46) | (56) | (38) | (55) | +8.9% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | (1) | 0 | 0 | — | 0 | (2.0%) | ||||||
| Free cash flow | (18) | (32) | (46) | (51) | (52) | 118 | (57) | (46) | (56) | (38) | (55) | +8.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 49 | 83 | 35 | 69 | 53 | 176 | 124 | 98 | 45 | 66 | 114 | +3.5% | |||||
| Net debt | (52) | (87) | (42) | (76) | (72) | (188) | (113) | (91) | (40) | (58) | (106) | +1.2% | ||||||
| Shareholders’ equity | 49 | 83 | 39 | 70 | 44 | 180 | 132 | 88 | 68 | 131 | 210 | +11.4% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (36.33) | (90.97) | (75.82) | (94.11) | (103.38) | 88.61 | (30.97) | (34.98) | (22.38) | (14.33) | (22.30) | +22.0 pt | |||||
| ROIC | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (180.14) | 0.00 | (135.38) | (36.33) | (35.11) | (36.3) pt | ||||||
| ROE | (38.20) | (97.66) | (85.04) | (111.11) | (142.60) | 107.30 | (34.72) | (47.57) | (33.88) | (17.51) | (25.97) | +20.7 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 31 | 43 | 55 | 59 | 67 | 57 | 44 | 40 | 23 | 23 | — | (3.3%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 3.66 | 0.03 | 0.01 | 0.02 | 0.32 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026
Ovid Therapeutics vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ENTX Entera Bio Ltd. | $520.0M | — (loss-making) | — (loss-making) | +200.00% (above 0%: growing) | n/m | −108.86% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| FTH Faeth Therapeutics, Inc. | $514.8M | — (loss-making) | — | — | n/m | −262.66% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NGNE Neurogene Inc. | $513.3M | — (loss-making) | — (loss-making) | — | n/m | −22.97% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLYM Climb Bio, Inc. | $509.5M | — (loss-making) | — | — | n/m | +3.73% (above 0%: growing) | — | 0.00% | Compare |
| YDES YD Bio Limited | $508.7M | — | — | — | — | — | — | — | Compare |
| SLBT SL SCIENCE HLDG | $504.7M | — | — | — | — | — | — | — | Compare |
| PBYI Puma Biotechnology, Inc. | $504.3M | 15.3× | 24.2× | +7.75% (above 0%: growing) | +33.33% (above 0%: growing) | −88.45% (below 0%: shrinking) | 77.92% | 13.42% | Compare |
| OVID Ovid Therapeutics | $503.9M | — (loss-making) | — (loss-making) | +463.85% (above 0%: growing) | n/m | −268.54% (below 0%: shrinking) | 100.00% | (2,141.61%) | |
| CAPR Capricor Therapeutics, Inc. | $500.0M | — (loss-making) | — (loss-making) | −7.92% (below 0%: shrinking) | n/m | −72.88% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| Median of peers | $509.1M | — | — | +7.75% | — | −80.66% | 77.92% | 0.00% |
Pay and ownership Proxy statement filed 27 April 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 1.93m | 3.73m | 87.63 |
| 2024 | 2.77m | 35.98k | 29.10 |
| 2023 | 2.14m | 2.98m | 100.31 |
Ownership
Directors and executive officers, together
7.00%
Entities affiliated with Janus Henderson
14.90%
SILV Fund Ltd.
9.90%
RA Capital Healthcare Fund, L.P.
9.90%
Affinity Healthcare Fund, LP
9.00%
Mutual Fund Series Trust, on behalf of Eventide Healthcare & Life Sciences Fund
8.10%
Entities affiliated with ADAR1 Capital Management, LLC
5.50%
Takeda Pharmaceutical Company Limited
5.10%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement